Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences cash
Cash and short-term investments held at the end of each period.
Castle Biosciences's cash was $277.67M at Sep 30, 2026. For fiscal 2025 it was $299.51M, up 2.2% from the year before. The highest annual figure on record is $409.85M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $299.51M | +2.2% |
| FY2024 | Dec 31, 2024 | $293.13M | +20.6% |
| FY2023 | Dec 31, 2023 | $243.10M | -6.0% |
| FY2022 | Dec 31, 2022 | $258.63M | -21.5% |
| FY2021 | Dec 31, 2021 | $329.63M | -19.6% |
| FY2020 | Dec 31, 2020 | $409.85M | +314.6% |
| FY2019 | Dec 31, 2019 | $98.85M | +2106.9% |
| FY2018 | Dec 31, 2018 | $4.48M | +269.6% |
| FY2017 | Dec 31, 2017 | $1.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $277.67M | -3.4% |
| Q2 FY2026 | Jun 30, 2026 | $266.81M | -3.3% |
| Q1 FY2026 | Mar 31, 2026 | $261.69M | -4.9% |
| Q4 FY2025 | Dec 31, 2025 | $299.51M | +2.2% |
| Q3 FY2025 | Sep 30, 2025 | $287.54M | +2.8% |
| Q2 FY2025 | Jun 30, 2025 | $275.93M | +6.3% |
| Q1 FY2025 | Mar 31, 2025 | $275.15M | +15.0% |
| Q4 FY2024 | Dec 31, 2024 | $293.13M | +20.6% |
| Q3 FY2024 | Sep 30, 2024 | $279.79M | +21.8% |
| Q2 FY2024 | Jun 30, 2024 | $259.69M | +15.2% |
| Q1 FY2024 | Mar 31, 2024 | $239.21M | +3.1% |
| Q4 FY2023 | Dec 31, 2023 | $243.10M | -6.0% |
| Q3 FY2023 | Sep 30, 2023 | $229.75M | -13.6% |
| Q2 FY2023 | Jun 30, 2023 | $225.51M | -17.4% |
| Q1 FY2023 | Mar 31, 2023 | $232.06M | -24.9% |
| Q4 FY2022 | Dec 31, 2022 | $258.63M | -21.5% |
| Q3 FY2022 | Sep 30, 2022 | $265.98M | -26.8% |
| Q2 FY2022 | Jun 30, 2022 | $273.17M | -25.8% |
| Q1 FY2022 | Mar 31, 2022 | $309.02M | -24.1% |
| Q4 FY2021 | Dec 31, 2021 | $329.63M | -19.6% |
| Q3 FY2021 | Sep 30, 2021 | $363.18M | +98.4% |
| Q2 FY2021 | Jun 30, 2021 | $368.34M | +104.9% |
| Q1 FY2021 | Mar 31, 2021 | $406.98M | +312.5% |
| Q4 FY2020 | Dec 31, 2020 | $409.85M | +314.6% |
| Q3 FY2020 | Sep 30, 2020 | $183.05M | +93.8% |
| Q2 FY2020 | Jun 30, 2020 | $179.76M | +929.1% |
| Q1 FY2020 | Mar 31, 2020 | $98.65M | +507.8% |
| Q4 FY2019 | Dec 31, 2019 | $98.85M | +2106.9% |
| Q3 FY2019 | Sep 30, 2019 | $94.48M | +2783.6% |
| Q2 FY2019 | Jun 30, 2019 | $17.47M | +235.6% |
| Q1 FY2019 | Mar 31, 2019 | $16.23M | +1239.1% |
| Q4 FY2018 | Dec 31, 2018 | $4.48M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.28M | – |
| Q2 FY2018 | Jun 30, 2018 | $5.21M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.21M | – |
See a number that looks wrong?